GAMMA Investing LLC Raises Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

GAMMA Investing LLC boosted its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 763.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,190 shares of the medical device company's stock after acquiring an additional 37,303 shares during the quarter. GAMMA Investing LLC owned 0.06% of Tandem Diabetes Care worth $808,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. AlphaQuest LLC lifted its position in Tandem Diabetes Care by 138.7% in the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after acquiring an additional 541 shares in the last quarter. Jones Financial Companies Lllp lifted its position in Tandem Diabetes Care by 195.8% in the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after acquiring an additional 748 shares in the last quarter. Assetmark Inc. lifted its position in Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after acquiring an additional 535 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after acquiring an additional 1,101 shares in the last quarter. Finally, Venturi Wealth Management LLC lifted its position in Tandem Diabetes Care by 5,955.9% in the 4th quarter. Venturi Wealth Management LLC now owns 2,059 shares of the medical device company's stock valued at $74,000 after acquiring an additional 2,025 shares in the last quarter.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ:TNDM traded down $0.19 during midday trading on Friday, hitting $20.22. The company had a trading volume of 1,120,610 shares, compared to its average volume of 1,498,784. The company has a debt-to-equity ratio of 1.99, a current ratio of 2.30 and a quick ratio of 1.81. The company has a market cap of $1.35 billion, a price-to-earnings ratio of -7.27 and a beta of 1.52. Tandem Diabetes Care, Inc. has a 12-month low of $15.75 and a 12-month high of $48.24. The company has a fifty day moving average of $20.25 and a two-hundred day moving average of $26.09.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The company had revenue of $234.42 million during the quarter, compared to analysts' expectations of $220.19 million. Tandem Diabetes Care had a negative return on equity of 57.33% and a negative net margin of 18.71%. The company's revenue for the quarter was up 22.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.65) earnings per share. On average, equities research analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TNDM has been the topic of several analyst reports. Citigroup upped their price objective on Tandem Diabetes Care from $20.00 to $24.00 and gave the company a "neutral" rating in a research report on Thursday, May 22nd. Morgan Stanley cut Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $45.00 to $22.00 in a report on Wednesday, March 5th. Wall Street Zen cut Tandem Diabetes Care from a "hold" rating to a "sell" rating in a report on Saturday. The Goldman Sachs Group lowered their price target on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Finally, Truist Financial assumed coverage on Tandem Diabetes Care in a report on Monday, June 16th. They set a "hold" rating and a $24.00 price target on the stock. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Tandem Diabetes Care has a consensus rating of "Hold" and a consensus target price of $33.43.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.